



Press release :

Melexis Q4 and FY 2012 results – Resilience reigns

Intermediate declaration by the Board of Directors.

leper, Belgium – February 6th, 2013, 07.00 hrs CET

The statutory auditors BDO Bedrijfsrevisoren BCV, have confirmed that their audit procedures, which have been substantially completed, have not revealed material adjustments which would have to be made to the accounting information included in this press release.

For the year 2012, sales were 247.0 million EUR, an increase of 7% compared to the previous year.

The EUR/USD exchange rate evolution had a positive impact of 4% compared to 2011.

Gross margin was 115.5 million EUR, an increase of 7% compared to 2011.

The operating result was 55.9 million EUR, an increase of 3% compared to last year.

R&D expenses were 16% of sales, Selling was at 3% of sales and G&A was at 5% of sales.

Net income was 51.5 million EUR, compared to 45.9 million EUR in 2011, an increase of 12%.

Sales for the 4th quarter of 2012 were 62.1 million EUR, an increase of 8% compared to the same quarter of the previous year and a decrease of 4% compared to the previous quarter.

The EUR/USD exchange rate evolution had a negative impact of 2% compared to the previous quarter.

Gross margin was 29.0 million EUR, an increase of 3% compared to the same quarter last year.

The operating result was 13.7 million EUR, a decrease of 5% compared to the same quarter of the previous year.

R&D expenses were 16% of sales, Selling remains stable at 3% of sales and G&A was at 5% of sales.

Net income was 16.5 million EUR, up 27% compared to the same quarter of last year.

1

Melexis purchased 189.473 shares during 2012 at an average price of 11.47 EUR. As a result, the total number of shares amounts to 346.141 at the end of 2012, representing 0.86% of shares outstanding.

Outlook

Melexis expects sales in the first quarter of 2013 to be around the level of 60 million EUR.

For FY 2013, Melexis expects to achieve mid to high single digit growth in sales, a gross profit margin above 45% and an operating margin above 21%, taking into account a EUR/USD exchange rate of 1.30.

Françoise Chombar, CEO of Melexis comments:

"Melexis further increased its sales versus the previous year, against the trend and amidst economic uncertainty. Our product portfolio hence can be considered pretty resilient. The first quarter of 2013 will mark the turning point towards renewed growth starting the second quarter. Seasonal effects, such as start-of-the-year price curve adjustments and the aftermath of both the Western and Chinese New Year, combined with depressed customer sentiment in the previous quarter and thus low order intake, weigh on the first quarter. This being said, Melexis guidance for 2013 remains intact, as we continuously bring innovation to the market, unwavering in our vision to engineer a sustainable future."





Financial Calendar

- Annual Shareholders Meeting: April 22, 2013
- Publication Q1 2013 Results: April 24, 2013
- Analyst Meeting: June 18, 2013
- Publication Q2/HY1 2013 Results: July 31, 2013
- Publication Q3 2013 Results: October 16, 2013
- Publication FY 2013 Results: February 5, 2014

The company's results will be discussed in a **conference call** on Wednesday, February 6th, 2013 at 17 hrs CET. The conference call will be in English. You have to register for this conference call in advance. You can register by clicking on the following link and filling out the requested information:

<https://eventreg1.conferencing.com/webportal3/reg.html?Acc=184341&Conf=186699>

Conference ID: 928583.

After registration, you will receive the conference call number, a participant user pin, conference pin and instructions on how to join the conference call. For security purposes all participants must register individually if they wish to join the call.

A replay number for this call is available for 7 days after the end of the conference call. The replay number for this call is +32 2 290 17 05, access code: 928583.

For further information:

Investor Relations

Phone: +32 13 67 07 79

Fax: +32 13 67 21 34

Email: investor@melexis.com

2

About Melexis

Melexis NV (Euronext Brussels: MELE) is a mixed signal semiconductor manufacturer. Melexis designs, develops, tests and markets advanced integrated semiconductor devices for the automotive industry. Our core experience supplying ICs for automotive electronics sustains the expansion into Application Specific Standard Products for industrial and consumer product applications. Melexis enthusiastically pursues its role as a component supplier whose innovations, while physically small, are the essential element in nearly every one of our customers' extraordinary systems. At Melexis we believe that "Small things make a big difference". Melexis' products include sensor, communication, actuator ICs and Application Specific Integrated Circuits (ASICs). Further information about Melexis can be found at <http://www.melexis.com>.

Disclaimer

Except for those statements that report the Company's historical results, the statements being made are forward looking statements. Actual results could differ materially from those projected in the forward-looking statements. Factors which could cause actual results to differ from expectations include the following: volatility in supply and demand affecting revenues and market prices, price and availability of silicon foundry, assembly and test prices, assembly and test subcontract capacity required to meet financial targets and/or meet backlog requirements, risks and delays associated with bringing up new production capabilities or with deliveries from subcontractors, timing and market acceptance of new products, increased expenses associated with new product acceptance of new products, increased expenses associated with new product introductions of process changes, delays in developing or achieving volume production of new products, which can result in delays or failure to contribute to revenues and profits, ability of the Company to maintain its customer and vendor base and delays in and/or inability in raising additional capital.






Consolidated Profit & Loss

CONFORM IAS		Quarter ended	Quarter ended	Year ended	Year ended
in k EUR		31/12/2012	31/12/2011	31/12/2012	31/12/2011
				audited	audited
Sales		62,097	57,308	247,041	230,661
	Cost of sales	-33,093	-29,147	-131,565	-122,451
Gross Margin		29,004	28,161	115,476	108,210
	R&D	-10,118	-8,602	-38,869	-34,342
	G&A	-3,226	-3,420	-13,149	-12,540
	Selling	-1,952	-1,710	-7,602	-6,882
	Other operating result				
Operating result		13,709	14,429	55,856	54,447
	Other expenses (net)	-9	23	-925	-1,166
Income before taxes		13,700	14,452	54,931	53,280
	Income taxes	2,774	-1,493	-3,402	-7,386
Net income		16,474	12,959	51,529	45,894
Net income per share in EUR		0.41	0.30	1.25	1.06


Consolidated Balance Sheet

CONFORM IAS		Year ended	Year ended
in k EUR		31/12/2012	31/12/2011
		audited	audited
Current Assets :			
	Cash and cash equivalents	21,317	17,806
	Current investments	3,928	4,605
	A/R Trade	35,359	37,802
	A/R from related parties	636	723
	Advance related parties		
	Tax assets	5,467	2,309
	Other current assets	8,002	4,833
	Inventories	38,359	36,943
Total current assets		113,067	105,022
Non current assets :			
	Costs of incorporation		
	Property, plant and equipment	60,004	51,354
	Financial assets	30	30
	Intangible fixed assets	2,113	1,943
	A/R directors		
	Other non-current assets	5,551	4,933
	Deferred tax assets	14,805	14,821
Total non current assets		82,503	73,081
Total assets		195,570	178,103





CONFORM IAS in k EUR	Year ended 31/12/2012 audited	Year ended 31/12/2011 audited
Liabilities and shareholders Equity		
Current liabilities :		
Bank loans and overdrafts		
Derivative financial instruments	1,103	964
Current portion of LT debt	34,648	4,648
A/P trade	12,329	8,163
Affiliated companies	4,680	5,117
Accrued taxes	3,572	2,005
Accrued expenses and payroll	4,263	6,562
Other current liabilities	1,374	3,063
Deferred income	581	625
Total current liabilities	62,550	31,146
Non current liabilities :		
LT debt less current portion	2,328	36,976
Deferred tax liabilities		
Other non-current liabilities	1,415	2,861
Total non current liabilities	3,743	39,837
Shareholders' equity :		
Shareholders' capital	565	565
Share premium		
Treasury shares	-3,818	-31,760
Revaluation reserve Hedge	-608	-494
Revaluation reserve Fair value	73	512
Legal reserve	57	57
Retained earnings	81,733	92,217
Current period's profit	51,529	45,894
Cumulative translation adjustment	-264	119
Equity attributable to company owners	129,267	107,110
Non controlling interests	10	10
Total shareholders equity	129,277	107,120
Total liabilities, shareholders' equity and minority interests	195,570	178,103





Consolidated Statements of Cash Flow

CONFORM IAS/IFRS (in k EUR)	Year ended 31/12/2012 audited	Year ended 31/12/2011 audited
Cash flow from operating activities		
Net income	51,529	45,894
Adjustments for :		
Operating activities	16,787	15,100
Deferred taxes	16	414
Capital grants	719	1,342
Depreciation and amortisation	15,210	11,948
Unrealized exchange results	1,124	560
Financial result	-282	836
Operating profit before working capital changes	68,316	60,995
A/R, Trade	2,346	-9,848
A/R, affiliates	86	8,073
Other current assets	-8,165	-1,331
Other non current assets	-617	-589
Inventories	-4,497	2,340
A/P	4,173	855
A/P affiliates	-436	-1,487
Accrued expenses	2,904	5,549
Other current liabilities	-1,690	1,347
Other non current liabilities	-1,351	-1,069
Interest paid	-2,000	-2,428
Income tax	-3,612	-4,194
Cash flow from operating activities	55,456	58,212
Cash flow from investing activities		
Acquisition of subsidiary, net of cash acquired		
Financial fixed assets		
Purchase of PPE and intangible assets (netted)	-20,749	-14,613
Interest received	1,220	1,189
Investments/proceeds/ from current investments (incl. financial instruments)	677	1,124
Cash provided from investing activities	-18,851	-12,300
Cash flows from financing activities		
Payment to acquire own shares	-2,399	-9,874
Proceeds/Repayment of long-and short-term debt	-4,648	-15,139
Proceeds/Repayment of bank loans and overdrafts		
Proceeds from (repayment of) related party financing		
Dividend payment	-26,036	-24,318
Capital Decrease		
Non controlling interests		
Cash provided from financing activities	-33,083	-49,331
CTA	-11	47
Increase/decrease in cash and cash equivalents	3,510	-3,374
Cash at beginning of the period	17,806	21,180
Cash at the end of the period	21,317	17,806





Sales per Geography

	Q4/12	Q4/11	2012	2011
APAC Asia Pacific	43%	40%	40%	39%
EMEA Europe - Middle-East - Africa	40%	44%	42%	44%
NALA North America - Latin America	17%	16%	18%	17%
TOTAL	100%	100%	100%	100%

Turnover per Business Unit

(in k EUR)	Q4/12	Q4/11	% CHANGE (Y-O-Y)
Sensors	37,299	32,187	16%
Wireless	3,356	2,891	16%
Actuators	17,316	16,581	4%
Opto	3,287	4,704	-30%
Other	838	945	-11%
TOTAL	62,097	57,308	8%

6

(in k EUR)	Q4/12	Q3/12	% CHANGE (Q-O-Q)
Sensors	37,299	38,542	-3%
Wireless	3,356	3,651	-8%
Actuators	17,316	17,586	-2%
Opto	3,287	3,889	-15%
Other	838	715	17%
TOTAL	62,097	64,383	-4%





(in k EUR)	2012	2011	% CHANGE (Y-O-Y)
Sensors	145,378	130,905	11%
Wireless	14,512	13,644	6%
Actuators	69,519	65,664	6%
Opto	14,636	17,506	-16%
Other	2,996	2,941	2%
TOTAL	247,041	230,661	7%

